DrugCentral 2023 🐕
2022 Update-Veterinary Drugs & Uses
Search
Structure 🔎
Similarity 🔎
Smart API
Redial
About
Download
L1000
FAQ
DrugCentral 2023 🐕
2022 Update-Veterinary Drugs & Uses
Search
Structure 🔎
Similarity 🔎
Smart API
Redial
About
Download
L1000
FAQ
Scroll
All
FDA-approved
EMA-approved
PMDA-approved
Target Card Uniprot Example:
P23975
telavancin 🐶
Veterinary Use |
Indications/Contra
| FAERs-F
| FAERs-M
| Orange Bk
| BioActivity |
Stem definition
Drug id
CAS RN
vancomycin related compounds
4116
372151-71-8
Description:
Molecule
Description
Molfile
Inchi
Smiles
Synonyms:
telavancin
arbelic
telavancin hydrochloride
vibativ
telavancin HCl
an anti-infective agent
Molecular weight: 1755.65
Formula: C80H106Cl2N11O27P
CLOGP: 0.78
LIPINSKI: 3
HAC: 38
HDO: 23
TPSA: 598.09
ALOGS: -5.08
ROTB: 30
Drug dosage:
None
ADMET properties:
Show
10
25
50
100
entries
Search:
Property
Value
Reference
t_half (Half-life)
6.70 hours
Lombardo F, Berellini G, Obach RS
CL (Clearance)
0.20 mL/min/kg
Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)
0.11 L/kg
Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)
0.07 %
Lombardo F, Berellini G, Obach RS
Showing 1 to 4 of 4 entries
Previous
1
Next
Approvals:
Show
10
25
50
100
entries
Search:
Date
Agency
Company
Orphan
Sept. 11, 2009
FDA
THERAVANCE BIOPHARMA
Showing 1 to 1 of 1 entries
Previous
1
Next
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
Show
10
25
50
100
entries
Search:
MedDRA adverse event term
Likelihood ratio
Likelihood ratio threshold
Patients taking drug having adverse event
Patients taking drug not having adverse event
Patients not taking drug having adverse event
Patients not taking drug not having adverse event
Hypertensive heart disease
81.11
59.76
14
291
4192
79739891
Tubulointerstitial nephritis
79.17
59.76
20
285
38215
79705868
Acute kidney injury
66.30
59.76
34
271
519370
79224713
Klebsiella infection
62.69
59.76
14
291
15706
79728377
Showing 1 to 4 of 4 entries
Previous
1
Next
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
Show
10
25
50
100
entries
Search:
Source
Code
Description
ATC
J01XA03
ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Glycopeptide antibacterials
CHEBI has role
CHEBI:33281
antibiotics
CHEBI has role
CHEBI:36047
antibacterial drugs
FDA EPC
N0000191281
Lipoglycopeptide Antibacterial
FDA EXT
N0000191280
Lipoglycopeptides
MeSH PA
D000900
Anti-Bacterial Agents
MeSH PA
D000890
Anti-Infective Agents
Showing 1 to 7 of 7 entries
Previous
1
Next
Drug Use
| Suggest Off label Use Form|
|View source of the data|
Show
10
25
50
100
entries
Search:
Disease
Relation
SNOMED_ID
DOID
Bacterial pneumonia
indication
53084003
DOID:874
Pneumonia due to Staphylococcus aureus
indication
441658007
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection
indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
indication
Complicated Skin and Skin Structure Infection
indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection
indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection
indication
Torsades de pointes
contraindication
31722008
Hypertensive disorder
contraindication
38341003
DOID:10763
Chronic heart failure
contraindication
48447003
Showing 1 to 10 of 18 entries
Previous
1
2
Next
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
Show
10
25
50
100
entries
Search:
Dissociation level
Dissociation constant
Type (acidic/basic)
pKa1
1.06
acidic
pKa10
12.69
acidic
pKa11
13.01
acidic
pKa12
13.37
acidic
pKa13
13.47
acidic
pKa14
12.0
Basic
pKa15
9.53
Basic
pKa16
8.33
Basic
pKa17
5.6
Basic
pKa2
2.59
acidic
Showing 1 to 10 of 17 entries
Previous
1
2
Next
Orange Book patent data (new drug applications)
Show
10
25
50
100
entries
Search:
Formulation strength
Trade name
Applicant
Application number
Approval date
Type
Dose form
Route
Patent number
Patent expiration date
Patent use
EQ 250MG BASE/VIAL
VIBATIV
CUMBERLAND PHARMS
N022110
Sept. 11, 2009
DISCN
POWDER
INTRAVENOUS
6635618
Sept. 11, 2023
METHOD FOR TREATING BACTERIAL INFECTION
EQ 750MG BASE/VIAL
VIBATIV
CUMBERLAND PHARMS
N022110
Sept. 11, 2009
RX
POWDER
INTRAVENOUS
6635618
Sept. 11, 2023
METHOD FOR TREATING BACTERIAL INFECTION
Showing 1 to 2 of 2 entries
Previous
1
Next
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
Show
10
25
50
100
entries
Search:
ID
Source
013290
NDDF
013291
NDDF
10925
IUPHAR_LIGAND_ID
167756
MMSL
26725
MMSL
30522
MMSL
3081362
PUBCHEM_CID
4029465
VUID
4029465
VANDF
4029466
VANDF
Showing 1 to 10 of 26 entries
Previous
1
2
3
Next
Pharmaceutical products:
Show
10
25
50
100
entries
Search:
Product
Category
Ingredients
NDC
Form
Quantity
Route
Marketing
Label
Vibativ
HUMAN PRESCRIPTION DRUG LABEL
1
52118-001
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
15 mg
INTRAVENOUS
NDA
33 sections
Vibativ
HUMAN PRESCRIPTION DRUG LABEL
1
52118-002
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
15 mg
INTRAVENOUS
NDA
33 sections
VIBATIV
HUMAN PRESCRIPTION DRUG LABEL
1
66220-315
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
15 mg
INTRAVENOUS
NDA
30 sections
VIBATIV
HUMAN PRESCRIPTION DRUG LABEL
1
66220-315
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
15 mg
INTRAVENOUS
NDA
30 sections
Showing 1 to 4 of 4 entries
Previous
1
Next
Search
Structure 🔎
Similarity 🔎
Smart API
Redial
About
Download
L1000
FAQ
telavancin